Skip to main content

Digene Signs Deal with Quest for Routine HPV DNA Testing

NEW YORK, Jan. 27 (GenomeWeb News) - Quest Diagnostics has agreed to market Digene's DNA-based test for human papillomavirus (HPV), Digene said today.

Under the three-year agreement, Quest will offer physicians Digene's HPV test for routine cervical cancer screening in conjunction with the Pap test.

Quest previously provided the test to physicians only for follow-up evaluation of ambiguous Pap test results. Digene's HPV test was approved in March 2003 for primary cervical cancer screening, in conjunction with a Pap test, in women age 30 and over.

The American College of Obstetricians and Gynecologists, the American Cancer Society, and the Association of Reproductive Health Professionals each have updated their screening guidelines to include HPV DNA testing as part of routine cervical cancer screening for women age 30 and older, Digene said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.